

## ISOLATION AND CHARACTERIZATION OF CONCANAMYCINS A, B AND C


HARUYASU KINASHI\*, KINUMI SOMENO and KENJI SAKAGUCHI

Mitsubishi-Kasei Institute of Life Sciences  
Minamiooya, Machida-shi, Tokyo 194, Japan

(Received for publication July 31, 1984)

Concanamycins A, B and C were isolated from the mycelium of *Streptomyces diastatochromogenes* S-45 as effective inhibitors of the proliferation of mouse splenic lymphocytes stimulated by concanavalin A. They represent a new class of 18-membered macrolide antibiotics, and are biologically active *in vitro* against several fungi and yeasts, but not against bacteria. Concanamycin A, the main component, has been identified with antifungal antibiotics, folimycin and A-661-I.

In the course of screening for immunologically active substances of microbial origin, three antibiotics were isolated from the mycelium of *Streptomyces diastatochromogenes* S-45 as effective inhibitors of the proliferation of mouse splenic lymphocytes stimulated by concanavalin A. These antibiotics were designated as concanamycins A, B and C according to their biological properties. Using this screening system, we also isolated two other new antibiotics, 2-11-A and B, whose structures have been determined as nonaketide antibiotics<sup>1)</sup>. The present paper describes the screening method, fermentation, isolation, and chemical and biological properties of concanamycins. The structures of concanamycins have been reported recently by us as shown in Fig. 1<sup>2-4)</sup>. They belong to a new class of 18-membered macrocyclic lactones with a long side chain which incorporates a six-membered hemiketal ring having 2-deoxy- $\beta$ -D-rhamnosyl group as a substituent. Comparison of concanamycins with other related antibiotics is also discussed. As a result of this study, concanamycin A has been identified with the antifungal antibiotics, folimycin<sup>5)</sup> and A-661-I<sup>6)</sup>, and concanamycins B and C seem to be new antibiotics.

Fig. 1. Structures of concanamycins A, B and C, and their *O*-methyl derivatives.

	R <sub>1</sub>	R <sub>2</sub>	R <sub>3</sub>
Concanamycin A	CH <sub>2</sub> CH <sub>3</sub>	H	CONH <sub>2</sub>
" B	CH <sub>3</sub>	H	CONH <sub>2</sub>
" C	CH <sub>2</sub> CH <sub>3</sub>	H	H
<i>O</i> -Methylconcanamycin A	CH <sub>2</sub> CH <sub>3</sub>	CH <sub>3</sub>	CONH <sub>2</sub>
" B	CH <sub>3</sub>	CH <sub>3</sub>	CONH <sub>2</sub>
" C	CH <sub>2</sub> CH <sub>3</sub>	CH <sub>3</sub>	H

## Screening Method


Mitogenesis assays were conducted using spleen cells from *ddY* mice cultured under the following conditions. The spleens were minced in small pieces with tweezers in serum-free RPMI 1640 medium, suspended by gentle pipetting, and passed through a Nylon screen to remove the debris. The cells were washed twice with RPMI 1640 by centrifugation at 1,500 rpm for 10 minutes. A total volume of 250  $\mu$ l of cell suspension containing  $1 \times 10^6$  cells was incubated in tissue culture plates in RPMI 1640 supplemented with 20 mM HEPES (*N*-2-hydroxyethylpiperazine-*N'*-2-ethanesulfonic acid, pH 7.7), 10% fetal calf serum, 60  $\mu$ g of kanamycin sulfate, and 4  $\mu$ g of concanavalin A per ml. Before addition of concanavalin A, 5  $\mu$ l of filter-sterilized fermentation broth or its dilution to be assayed was added. Cultures were incubated at 37°C in 95% air - 5% CO<sub>2</sub> atmosphere for 50 hours and pulsed with 0.2  $\mu$ Ci of [<sup>3</sup>H]thymidine for the last 20 hours of incubation period. The cells were harvested on glass filter papers using a cell harvester, washed with water, and after drying the amount of [<sup>3</sup>H]-thymidine incorporated into the cells was measured in a liquid scintillation counter. In this screening system, the fermentation broth of *S. diastatochromogenes* S-45 was found to inhibit the incorporation of [<sup>3</sup>H]thymidine into the cells.

## Fermentation

The fermentation inoculum (500 ml) was prepared by two stage submerged culture, in a medium consisting of 1% starch, 1% Polypeptone, 1% molasses and 1% meat extract in tap water (initial pH 7.2). This was transferred into a 30-liter fermentor containing 15 liters of the medium composed of 1% glucose, 1% starch, 1.5% soybean meal, 0.4% dry yeast, 0.2% NaCl, 0.1% meat extract and 0.005% K<sub>2</sub>HPO<sub>4</sub> (initial pH 8.8). The fermentation was carried out at 27°C for 3 days under aeration (10 liters/minute) and agitation (200 rpm). The course of a typical fermentation is illustrated in Fig. 2. Determination of antibiotic activity was made by the method described above and the maximum inhibitory activity in the mycelium was reached after about 70 hours of fermentation.

Fig. 2. Time course of the production of concanamycins in the mycelium of *S. diastatochromogenes* S-45.

○ Packed cell volume (%), □ pH, △ incorporation of [<sup>3</sup>H]thymidine into mouse splenic lymphocyte cells (%). The mycelium was extracted with the same volume of MeOH as that of the fermentation broth, diluted 10<sup>3</sup> times, and 5  $\mu$ l was added to each well of tissue culture plates.




## Isolation

Since the inhibitory activity was mostly present in the mycelium, the mycelial cake was extracted with methanol three times. The extract was concentrated to an aqueous solution, which was extracted two times with ethyl acetate at pH 8. After washing with water at pH 3, the ethyl acetate extract was evaporated *in vacuo* to a brown syrup. This was dissolved in benzene and adsorbed on a silica gel column. After washing with benzene and a mixture of benzene and ethyl acetate (1:1) successively, the antibiotics were eluted with ethyl acetate. The crude complex obtained by combination of the active fractions was checked by silica gel HPLC with chloroform and methanol (40:1), indicating the presence of two separable components as shown in Fig. 3a. Standing in  $10^{-3}$  N HCl - methanol at room temperature overnight, this crude complex showed three peaks as illustrated in Fig. 3b. This change of chromatographic behavior proved later to be caused by *O*-methylation of a hemiketal hydroxyl group of three components contained in the crude complex by treating with HCl - methanol, although concanamycin C was somewhat difficult to be transformed. *O*-Methylconcanamycins A and B gave discrete peaks on HPLC with chloroform and methanol as shown in Fig. 3b, even though the hydroxyl forms could not be separated with any solvent systems tested. Therefore, a mixture of the methylated derivatives were purified by silica gel column chromatography with chloroform and methanol (30:1 and 20:1), and the purified derivatives obtained were respectively converted to their corresponding hydroxyl forms by shaking overnight in a mixture of chloroform and aqueous 0.1 N HCl. The hydroxyl forms of concanamycins were further purified by silica gel thin-layer chromatography with benzene and ethyl acetate (1:4), and finally by Sephadex LH-20 column chromatography with isopropyl alcohol as developing solvent. The  $R_f$  values on silica gel thin-layer of the free hydroxyl and *O*-methyl forms of three components are listed in Table 1.

Fig. 3. High pressure liquid chromatograms of crude concanamycins before (a) and after (b) treating with  $10^{-3}$  N HCl - MeOH.

Conditions: Porasil T, 1 m  $\times$  1 mm;  $\text{CHCl}_3$ -MeOH (40:1), 3 ml/minute; UV detection at 254 nm.



## Chemical Characterization

Physico-chemical properties of concanamycins A, B and C are listed in Table 2. The UV spectra of these antibiotics indicated in common the presence of an  $\alpha,\beta,\gamma,\delta$ -unsaturated ester (285 nm) and a


Table 1.  $R_f$  values on silica gel TLC of the free hydroxyl and *O*-methylconcanamycins.

	A-OH	A-OMe	B-OH	B-OMe	C-OH	C-OMe
Solvent 1	0.27	0.28	0.27	0.24	0.33	0.36
Solvent 2	0.25	0.33	0.24	0.23	0.27	0.39
Solvent 3	0.18	0.23	0.18	0.16	0.28	0.35

Solvent 1  $\text{CHCl}_3$  - MeOH (10:1), solvent 2  $\text{C}_6\text{H}_6$  - EtOAc (1:4), solvent 3  $\text{CHCl}_3$  - 1-PrOH (10:1). Silica gel 60 F-254 plates (Merck, 10 cm, 0.25 mm) were used.

Table 2. Physico-chemical properties of concanamycins.

	A	B	C
Nature	Colorless thin plates	White amorphous powder	Colorless thin plates
MP	162~163.5°C	—	153~155°C
Molecular formula	C <sub>46</sub> H <sub>75</sub> NO <sub>14</sub>	C <sub>46</sub> H <sub>73</sub> NO <sub>14</sub>	C <sub>45</sub> H <sub>74</sub> O <sub>13</sub>
MS ( <i>m/z</i> )	865 (in beam EI, M <sup>+</sup> )	874 (FD, M+Na <sup>+</sup> )	804 (EI, M <sup>+</sup> -H <sub>2</sub> O)
UV λ <sub>max</sub> <sup>2-PrOH</sup> (nm, ε)	245 (40,500), 285 (19,800)	245 (38,000), 285 (18,500)	245 (40,800), 285 (19,700)
IR ν <sub>max</sub> <sup>CHCl<sub>3</sub></sup> (cm <sup>-1</sup> )	3560~3500, 3420, 1718, 1690, 1585, 1455, 1385, 1363	3545, 3430, 1720, 1690, 1585, 1450, 1380, 1360,	3685, 3590, 3415, 1690, 1607, 1450, 1365
[α] <sub>D</sub> <sup>25</sup>	-21.7° (c 1.0, MeOH)	-20.6° (c 0.63, 2-PrOH)	-22.6° (c 0.50, 2-PrOH)

Fig. 4. 90 MHz <sup>13</sup>C NMR spectrum of concanamycin A.

conjugated diene (245 nm). Concanamycin A crystallized from aqueous methanol as colorless thin plates, mp 162~163.5°C. The elemental analysis did not allow an unambiguous deduction of the molecular formula as in the cases of other macrolide antibiotics. Therefore, the accurate molecular formula C<sub>46</sub>H<sub>75</sub>NO<sub>14</sub> of concanamycin A was established on the basis of mass and <sup>13</sup>C NMR spectral analyses, and finally confirmed by the structure determination by chemical and spectroscopic methods. Namely, the in beam EI-MS gave a molecular ion at *m/z* 865, and the 90 MHz <sup>13</sup>C NMR spectrum (Fig. 4) indicated the presence of 46 carbon atoms although some carbon signals were very broad, perhaps because of the conformational flexibility of the macrolide ring. (All NMR spectra were measured at 50°C in CDCl<sub>3</sub> with addition of D<sub>2</sub>O except otherwise described.) The <sup>13</sup>C NMR spectrum indicated ten C-methyl carbons (δ 6.9~17.6), ten methylene and methyne carbons (δ 19.8~45.0), two methoxy carbons (δ 55.5 and 59.1), ten oxymethyne carbons (δ 69.7~81.5), an acetal and a ketal carbons (δ 96.6 d and 99.5 s), ten olefinic carbons (δ 123.6~142.1), and a carbamoyl and an ester carbons (δ 157.6 s and 166.3 s). Since eight of ten olefinic carbons were assigned to an α,β,γ,δ-unsaturated ester and a conjugated diene, concanamycin A contains an isolated double bond. The acetal signal was assigned to the anomeric carbon of 4-carbamyl-2-deoxy-β-D-rhamnose and the ketal signal to C-21 of the six-membered hemiketal ring (see below).

The 270 MHz  $^1\text{H}$  NMR spectrum of concanamycin A is shown in Fig. 5. The assignments of the proton signals could be accomplished by the aid of conventional proton spin decoupling, difference spectrum as well as NOE experiments, and are listed in Table 3. Before addition of  $\text{D}_2\text{O}$ , the spec-

Fig. 5. 270 MHz  $^1\text{H}$  NMR spectrum of concanamycin A.




Table 3.  $^1\text{H}$  NMR assignments of concanamycin A<sup>a</sup>.

C2-OCH <sub>3</sub>	3.57 s	H18	2.16 m
H3	6.38 s	C18-CH <sub>3</sub>	0.83 d (7.0)
C4-CH <sub>3</sub>	1.98 br s	H19	4.04 dd (10.5, 1.5)
H5	5.80 br d (10.5)	H20	1.75 dq (7.0, 2.0)
H6	2.73 m	C20-CH <sub>3</sub>	1.05 d (7.0)
C6-CH <sub>3</sub>	1.06 d (6.0)	C22-H <sub>2</sub>	—
H7	3.82 dd (8.0, 2.5)	H23	3.76 m
H8	1.50 m	H24	1.25 m
C8-CH <sub>2</sub> CH <sub>3</sub>	1.26 m	C24-CH <sub>3</sub>	0.89 d (6.6)
C8-CH <sub>2</sub> CH <sub>3</sub>	0.88 t (7.0)	H25	3.97 dd (10.0, 7.5)
H9	3.25 br d (11.0)	H26	5.31 ddq (15.0, 7.5, 1.5)
H10	2.20 obsc	H27	5.54 dq (15.0, 6.4)
C10-CH <sub>3</sub>	1.05 obsc	C28-H <sub>3</sub>	1.59 d (6.4)
C11-H <sub>2</sub>	1.96 m	H1'	4.55 dd (9.0, 1.5)
C12-CH <sub>3</sub>	1.83 br s	H2'ax	1.65 m
H13	5.80 br d (10.5)	H2'eq	2.17 m
H14	6.54 dd (15.0, 10.5)	H3'	3.71 m
H15	5.23 dd (15.0, 9.0)	H4'	4.27 t (9.3)
H16	3.86 t (9.0)	H5'	3.35 dq (9.3, 6.0)
C16-OCH <sub>3</sub>	3.26 s	C6'-H <sub>3</sub>	1.24 d (6.0)
H17	5.03 br d (9.0)	OCO-NH <sub>2</sub> <sup>b</sup>	4.87 s

<sup>a</sup> Chemical shifts are in ppm downfield of internal TMS. Coupling constants in Hz are given in parentheses.

<sup>b</sup> Measured before addition of  $\text{D}_2\text{O}$ .

— Not determined.

obsc: Obscured (overlapping signals).

trum indicated the presence of a carbamoyl group ( $\delta$  4.87 s), which was also ascertained by the IR spectrum (Fig. 6,  $1718\text{ cm}^{-1}$ ) and the positive color reaction with chlorine-pyrazolinone-cyanide reagent. Extensive  $^1\text{H}$  NMR analysis of the degradation products and concanamycin A itself revealed the gross structure of concanamycin A as shown in Fig. 1<sup>2,3</sup>.

The  $^1\text{H}$  NMR spectrum of *O*-methylconcanamycin A indicated the presence of three methoxy groups at  $\delta$  3.04, 3.25 and 3.67. This strongly suggested methylation of the hemiketal hydroxyl group, and this was further supported by the observed downfield shift of C-21 carbon at  $\delta$  99.5 in the  $^{13}\text{C}$  NMR spectrum of concanamycin A to  $\delta$  104.1 for *O*-methylconcanamycin A.

Concanamycin B is an amorphous white powder. All attempts to crystallize the compound have failed so far. The physico-chemical properties of concanamycin B are very similar with those of concanamycin A. Since the molecular formula was deduced to be  $\text{C}_{40}\text{H}_{73}\text{NO}_{14}$  from the FD mass spectrum ( $m/z$  874,  $\text{M} + \text{Na}^+$ ), concanamycin B is different from concanamycin A only by one methylene unit. The  $^{13}\text{C}$  NMR and  $^1\text{H}$  NMR spectra of concanamycin B are shown in Figs. 7 and 8 respectively, although some carbon signals at high field are not seen because of signal broadening. The IR

Fig. 6. IR spectrum of concanamycin A in  $\text{CHCl}_3$ .





Fig. 7. 90 MHz  $^{13}\text{C}$  NMR spectrum of concanamycin B.



spectrum was almost identical with that of concanamycin A. Precise  $^1\text{H}$  NMR analysis of concanamycin B and its degradation products revealed that an ethyl group attached to C-8 of concanamycin A was replaced by a methyl group in concanamycin B<sup>4)</sup>.

Concanamycin C crystallized from methanol as colorless thin plates, mp  $153\sim 155^\circ\text{C}$  (the previously reported solvent for crystallization is corrected here). The molecular formula  $\text{C}_{45}\text{H}_{74}\text{O}_{13}$  was also deduced from the mass spectrum ( $m/z$  804,  $\text{M}^+ - \text{H}_2\text{O}$ ). Concanamycin C is different from concanamycins A and B in the respect that it does not contain a nitrogen atom in the molecule. The  $^{13}\text{C}$  NMR (Fig. 9),  $^1\text{H}$  NMR (Fig. 10) and IR spectra (Fig. 11), and the negative color reaction with reagent the described above revealed the absence of a carbamoyl group in concanamycin C, which was consistent with the molecular formula. Furthermore, the upfield-shifted signal of H-4' ( $\delta$  3.06 t,  $J=8.7$  Hz) of concanamycin C indicated decarbamylation of the hydroxyl group attached to C-4'.

#### Biological Properties

The effect of concanamycins on the proliferation of mouse splenic lymphocytes stimulated by concanavalin A was studied by the method used in screening and the result is shown in Fig. 12. Concanamycins A, B and C indicated 99, 82 and 88% inhibition of the incorporation of [ $^3\text{H}$ ]thymidine into the cells respectively at the concentration of  $1 \times 10^{-3}$   $\mu\text{g}/\text{ml}$ , and 99% or more inhibition at  $3 \times$

Fig. 8. 270 MHz  $^1\text{H}$  NMR spectrum of concanamycin B in  $\text{CDCl}_3$  without addition of  $\text{D}_2\text{O}$ .





Fig. 9. 90 MHz  $^{13}\text{C}$  NMR spectrum of concanamycin C.



$10^{-3}$   $\mu\text{g/ml}$ . Since concanavalin A was considered to be a T-cell specific mitogen, we tested the effect of concanamycins on other types of mitogens. They also inhibited the proliferation of mouse splenic lymphocytes stimulated by pokeweed mitogen (B-cell mitogen) and mixed lymphocyte reaction (*ddY*, nontreated; BALB/C, mitomycin C treated), respectively (unpublished results). These results suggested that the inhibition by these antibiotics was not specific for the stimulation by concanavalin A.

Fig. 10. 270 MHz  $^1\text{H}$  NMR spectrum of concanamycin C.





Table 4. Antimicrobial spectrum of concanamycins.

	Media	MIC ( $\mu\text{g/ml}$ )		
		A	B	C
<i>Escherichia coli</i>	1	>100	>100	>100
<i>Bacillus subtilis</i>	1	>100	>100	>100
<i>B. cereus</i>	1	>100	>100	>100
<i>Micrococcus varians</i>	1	>100	>100	>100
<i>Proteus vulgaris</i>	1	>100	>100	>100
<i>Pseudomonas aeruginosa</i>	1	>100	>100	>100
<i>P. fluorescens</i>	1	>100	>100	>100
<i>Micrococcus luteus</i>	1	>100	>100	>100
<i>Serratia marcescens</i>	1	>100	>100	>100
<i>Staphylococcus aureus</i>	1	>100	>100	>100
<i>Mycobacterium phlei</i>	2	>100	50	>100
<i>Candida albicans</i>	2	>100	>100	>100
<i>Kluyveromyces lactis</i>	2	>100	>100	>100
<i>Saccharomyces cerevisiae</i>	2	<0.39	<0.39	<0.39
<i>S. sake</i>	2	<0.39	<0.39	<0.39
<i>Alternaria citri</i>	2	<0.39	<0.39	<0.39
<i>Aspergillus niger</i>	2	>100	>100	>100
<i>Colletotrichum coccodes</i>	2	>100	12.5	>100
<i>Cryptococcus albidus</i>	2	>100	>100	>100
<i>Fusarium solani</i>	2	>100	>100	>100
<i>Pellicularia filamentosa</i>	2	>100	>100	>100
<i>Penicillium citrinum</i>	2	1.56	1.56	1.56
<i>Piricularia oryzae</i>	2	25	25	25
<i>Trichophyton asteroides</i>	2	>100	>100	>100

1: Nutrient agar, 2: nutrient agar + 1% glucose.



Fig. 11. IR spectrum of concanamycin C in  $\text{CHCl}_3$ .

The antimicrobial activities of concanamycins were measured by agar dilution method and are listed in Table 4. All three components indicated the inhibitory activity against some of fungi and yeasts, but not against bacteria. In a preliminary incorporation experiment using *Saccharomyces cerevisiae* cell suspension and labeled precursors, DNA and RNA syntheses were inhibited in this order, but protein synthesis was not inhibited (unpublished result).


Acute toxicity was studied with *ddY* mice. All of the mice survived intraperitoneal injection of 0.1 mg/kg of each component, but all of the mice died at the injection of 1.0 mg/kg. Studies of other types of biological activities of concanamycins may prove interesting, because a related 16-membered macrocyclic lactone, L-681,110 was found as an inhibitor of the sodium and potassium ion activated adenosinetriphosphatase.<sup>7)</sup>

### Discussion

Concanamycins A, B and C belong to a new class of 18-membered macrocyclic lactones\* with a long side chain which incorporates a six-membered hemiketal ring having 2-deoxy- $\beta$ -D-rhamnosyl group as a substituent. These were compared with other known antibiotics having some points of similarity in physical, chemical and biological properties. There are many antibiotics having similar UV spectra as those of concanamycins (285 and 245 nm). Among them the antifungal antibiotics, folimycin<sup>5)</sup> and A-661-I<sup>6)</sup>, are the most similar to concanamycin A. Folimycin and A-661-I show UV absorption maxima at 245 and 284 nm, and 246 and 285 nm respectively. Although the other physico-chemical properties of these two antibiotics described in the literature are somewhat different

Fig. 12. Effect of concanamycins on the proliferation of mouse splenic lymphocytes stimulated by concanavalin A.

○ Concanamycin A, □ B, △ C. The samples were dissolved in EtOH, and 5  $\mu$ l was added to each well of tissue culture plates. Each point represents the mean of quadruplicate measurement.



\* Concanamycins are the second example of the 18-membered macrolide antibiotics following borrelidin<sup>5)</sup>.

from those of concanamycin A, direct comparison of these compounds on silica gel TLC revealed their identity. Furthermore, folimycin and A-661-I also gave the identical *O*-methyl derivative with that of concanamycin A by treating with  $10^{-3}$  N HCl - methanol; this supported the above conclusion. Recently, ŌMURA *et al.* reported the structural elucidation of virustomycin which has the identical aglycone with that of concanamycin A plus flavensomycinic acid attached to it<sup>6)</sup>. New 16-membered macrocyclic lactones, hygrolidin<sup>10)</sup>, bafilomycins<sup>11)</sup> and L-681,110<sup>7)</sup> also contain an  $\alpha,\beta,\gamma,\delta$ -unsaturated lactone and a conjugated diene. HAGENMAIER *et al.* reported the methylation of a hemiketal hydroxyl group in bafilomycins during the isolation procedure<sup>12)</sup>.

Concanamycin B also contains a nitrogen atom ( $C_{45}H_{73}NO_{14}$ ) and is different from concanamycin A only by one methylene unit. Closely related with concanamycins A and B are ikutamycin<sup>13)</sup>, antibiotic 1-81d-1S<sup>14)</sup>, scopathricin II<sup>15)</sup>, antibiotic PA 128<sup>16)</sup>, MD129-C2<sup>17)</sup>, setamycin<sup>18)</sup> and SF-1540 A and B<sup>19)</sup>. Particularly, scopathricin II is very similar with concanamycins A and B in the respect that it gave the 4-*O*-carbamate of methyl 2-deoxyrhamnoside by methanolysis. The latter three antibiotics seem to be different from concanamycins A and B, because they have a positive optical rotation. KONDO *et al.* also reported the formation of SF-1540 M by treating SF-1540 A with methanol<sup>20)</sup>. This compound seems to be formed by *O*-methylation of a hemiketal hydroxyl group of SF-1540 A. Since these related antibiotics have not been well characterized, the final conclusion about the identity of these antibiotics and concanamycins A and B is not possible until a direct comparison can be performed.

Concanamycin C differs from concanamycins A and B because it does not contain a nitrogen atom ( $C_{45}H_{74}O_{13}$ ). At this point, concanamycin C is related to scopamycins A and B<sup>21)</sup>, scopathricin I<sup>15)</sup>, humidine<sup>22)</sup> and neohumidine<sup>23)</sup>. In particular, scopathricin I is similar to concanamycin C, since it gave methyl 2-deoxyrhamnoside by methanolysis. Scopamycin A is clearly distinguished from concanamycin C because it yielded 2-*O*-methyl-L-rhamnose on treatment with acid<sup>24)</sup>. It is very interesting that closely related antibiotics contain derivatives of L- and D-rhamnose. Further characterization of these antibiotics or direct comparison are necessary for identification.

#### Acknowledgment

We thank to Drs. K. ISONO and S. SUZUKI, the Institute of Physical and Chemical Research, for providing the producing organism of concanamycins. We also thank to Drs. T. HIGASHIJIMA, T. MIYAZAWA, K. FURIHATA, H. SETO and N. ŌTAKE, the University of Tokyo, for NMR spectra, and Dr. S. HARADA, Takeda Chemical Industries and Dr. J. SHOJI, Shionogi Research Laboratories, for the samples of folimycin and A-661-I, respectively.

#### References

- 1) KINASHI, H. & K. SAKAGUCHI: Structures of antibiotics 2-11-A and B. *Agric. Biol. Chem.* 48: 245~247, 1984
- 2) KINASHI, H.; K. SOMENO, K. SAKAGUCHI, T. HIGASHIJIMA & T. MIYAZAWA: Alkaline degradation products of concanamycin A. *Tetrahedron Lett.* 22: 3857~3860, 1981
- 3) KINASHI, H.; K. SOMENO, K. SAKAGUCHI, T. HIGASHIJIMA & T. MIYAZAWA: Structure of concanamycin A. *Tetrahedron Lett.* 22: 3861~3864, 1981
- 4) KINASHI, H.; K. SAKAGUCHI, T. HIGASHIJIMA & T. MIYAZAWA: Structures of concanamycins B and C. *J. Antibiotics* 35: 1618~1620, 1982
- 5) YAMAMOTO, H.; K. NAKAZAWA, S. HORII & A. MIYAKE: Studies on agricultural antibiotic. Folimycin, a new antibiotic produced by *Streptomyces neyagawaensis* nov. sp. *Nippon Nogeikagaku Kaishi* 34: 268~272, 1960
- 6) SHOJI, J. *et al.* (Shionogi): Method for preparation of new antibiotic, A-661-I. *Japan Kokai* 74-126,896, Dec. 4, 1974
- 7) HENSENS, O. D.; R. L. MONAGHAN, L. HUANG & G. ALBERS-SCHONBERG: Structure of the sodium and potassium ion activated adenosinetriphosphatase inhibitor L-681,110. *J. Am. Chem. Soc.* 105: 3672~3679, 1983
- 8) KELLER-SCHIERLEIN, W.: Stoffwechselprodukte von Mikroorganismen. 55. Über die Konstitution des

- Borreliidins. *Helv. Chim. Acta* 50: 731~753, 1967
- 9) ŌMURA, S.; N. IMAMURA, K. HINOTOZAWA, K. OTOGURO, G. LUKACS, R. FAGHIH, R. TOLMANN, B. H. ARISON & J. L. SMITH: The structure of virustomycin A. *J. Antibiotics* 36: 1783~1786, 1983
  - 10) SETO, H.; H. AKAO, K. FURIHATA & N. ŌTAKE: The structure of a new antibiotic, hygrolidin. *Tetrahedron Lett.* 23: 2667~2670, 1982
  - 11) WERNER, G.; H. HAGENMAIER, K. ALBERT, H. KOHLSHORN & H. DRAUTZ: The structure of the bafilomycins, a new group of macrolide antibiotics. *Tetrahedron Lett.* 24: 5193~5196, 1983
  - 12) WERNER, G.; H. HAGENMAIER, H. DRAUTZ, A. BAUMGARTNER & H. ZÄHNER: Metabolic products of microorganisms. 224. Bafilomycins, a new group of macrolide antibiotics. Production, isolation, chemical structure and biological activity. *J. Antibiotics* 37: 110~117, 1984
  - 13) SAKAGAMI, Y.; A. UEDA & S. YAMABAYASHI: Studies on ikutamycin, a new antifungal antibiotic. I. Isolation and properties of ikutamycin. *J. Antibiotics, Ser. A* 20: 299~303, 1967
  - 14) HERMANN, E. C.; L. M. LARSON & W. A. PRICE, JR. (E.I. du Pont de Nemours & Co.): Antibiotic and production thereof. US 2,805,185, Sept. 3, 1957
  - 15) TAKAHASHI, S.; J. B. MCALPINE & J. W. CORCORAN: Scopathricins I and II: A preliminary report and possible correlation of scopamycin A. Abstracts Papers of 13th Intersci. Conf. on Antimicrob. Agents & Chemother., No. 141, Washington D.C., 1973
  - 16) RAO, K. V. & J. E. LYNCH: PA 128, a new antiprotozoal antibiotic. *Antibiot. Chemother.* 8: 437~440, 1958
  - 17) OKAMI, Y.; H. UMEZAWA & M. MATSUOKA (Inst. Microb. Chem.): Method for preparation of antibiotic, MD129-C2 substance. *Japan Kokai* 74-85,296, Aug. 15, 1974
  - 18) ŌMURA, S.; K. OTOGURO, T. NISHIKIORI, R. ŌIWA & Y. IWAI: Setamycin, a new antibiotic. *J. Antibiotics* 34: 1253~1256, 1981
  - 19) KONDO, Y.; T. SHOMURA, H. WATANABE, Y. SUZUKI, S. INOUE & T. NIIDA: Studies on new antibiotics SF-1540 A and B substances. I. Producing microorganism, and isolation and physico-chemical and biological characterization. *Sci. Reports of Meiji Seika Kaisha* 17: 15~24, 1978
  - 20) KONDO, Y.; K. MIYAUCHI & S. INOUE: Studies on new antibiotics SF-1540 substance. II. Preparation and biological property of SF-1540 M, a new derivative of SF-1540 A substance. *Sci. Reports of Meiji Seika Kaisha* 18: 1~6, 1979
  - 21) HUTTER, R.; W. KELLER-SCHIERLEIN, J. NUESCH & H. ZÄHNER: Stoffwechselprodukte von Mikroorganismen. 48. Scopamycine. *Arch. Mikrobiol.* 51: 1~8, 1965
  - 22) NAKAZAWA, K.; M. SHIBATA, H. YAMAMOTO, T. KANZAKI & E. HIGASHIDE: Studies on Streptomycetes. Humidine, an antifungal antibiotic produced by *Streptomyces humidus*. *Nippon Nogeikagaku Kaishi* 32: 713~716, 1958
  - 23) YAMAMOTO, H.; T. IWASA, M. SHIBATA, K. MIZUNO & A. MIYAKE: *Streptomyces multispiralis* nov. sp. and a new antibiotic, neohumidine. *Agric. Biol. Chem.* 29: 360~368, 1965
  - 24) MCALPINE, J. B. & J. W. CORCORAN: Scopamycin. II. Identification of the sugar moiety of scopamycin A as 2-O-methyl-L-rhamnose. *J. Antibiotics* 24: 51~56, 1971